<h4>Background</h4>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is increasingly used for obesity treatment, including in individuals without diabetes. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.